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database. Baseline demographics, HbA1C, co-morbidities, health
care utilization, pharmacy copayment, and concomitant fol-
lowup antidiabetic medications were controlled. Costs were
evaluated using actual paid claims by health insurance, adjusting
for inﬂation to the most current year value. RESULTS: Patients at
baseline had same mean age 54 years, 44 vs. 52% female, base-
line HbA1C 9.3 vs. 8.9%, access to endocrinologist 36 vs. 46%,
average number of oral antidiabetic agents 2.3 vs. 2.0, patients
with medical insurance claims for hypoglycemia 3.2 vs. 4.3%,
Charlson comorbidity score for overall comorbidities 0.64 vs.
0.82, and 6-month total health care costs $8,797 vs. $12,924 in
glargine vs. NPH initiator groups, respectively. Adjusted 1-year
mean HbA1C was 8.05 vs. 8.51% (d = -0.45, p = 0.0036) and
2-year mean HbA1C was 8.03 vs. 8.37% (d = -0.33, p = 0.0099)
for glargine and NPH, respectively. At end of 2 years, 16.6%
NPH initiators dispensed glargine prescriptions while 2.7%
glargine initiators dispensed NPH prescriptions. Adjusted rate
of patients per quarter in the ﬁrst year with medical claims
for hypoglycemia was 1.7 vs. 2.9% (d = -1.2%, p = 0.0559)
and 2-year quarterly rate was 1.55 vs. 2.51% (d = -0.96%,
p = 0.0139). Adjusted 1-year total health care costs were
$16,184 vs. $21,104 (quarterly d = -$1,034, p = 0.0372) and
2-year costs was $30,032 vs. $42,208 (quarterly d = -$1,522,
p = 0.0029). CONCLUSION: Initiation of insulin glargine, rela-
tive to NPH, was associated with sustained improvements in
glycemic control with lower rate of medically claimed hypogly-
cemia and lower total health care expenditures in patients with
T2DM.
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OBJECTIVES: To compare 1-year health care utilization and
costs in patients initiating insulin glargine vs NPH. METHODS:
Patients with T2DM (03/2001..C03/2005) who failed oral agents
and initiated insulin glargine or NPH were evaluated using
the Integrated Health Care Information System, a US managed
care health plan database. Patients were continuously enrolled
with managed care health plans for °Ý6 months before and
12 months after insulin initiation. Propensity score matched
NPH to glargine initiators by baseline demographics, HbA1c,
co-morbidities, health care utilization, and pharmacy copay-
ment. Conditional logistic regression, McNemar’s test, and
paired t-test were used to compare subsequent utilizations/ costs
between two insulin groups. Costs were paid by health insurance,
adjusting for inﬂation to the most current year value in database.
RESULTS: Matched sample (n = 1,468) was 46% female, mean
age 54.6 yrs., A1C 9.2%, Charlson Comorbidity Index (CCI)
0.69, metformin-use 77.6%, sulfonylureas 77.6%, and thiazo-
lidinedione 56%. Before matching, glargine initiators were more
likely than NPH initiators to be female, had higher HbA1c, CCI,
more use of TZD, sulfonylurea and statins, fewer visits to an
endocrinologist, higher out-of-pocket drug copayment, lower
total health care utilization and associated costs (except diabetes
medications). After propensity score matching, no differences
remained between matched pairs. During 12-month follow-up,
glargine initiators showed a lower hospitalization rate (OR:0.73,
95%CI [0.57–0.94], P = 0.0124) while outpatient and emer-
gency service utilization was not statistically different between
groups. Number needed to treat with glargine was 17 (95% CI:
9–59) to avoid hospitalization for a patient. For the same
follow-up period, glargine use on average cost $532 vs. $293 for
NPH (P < 0.0001) and $2097 vs $1820 for all antidiabetic
medications (P < 0.0001). CONCLUSION: Initiation of insulin
glargine is associated with lower rate of hospitalization com-
pared to NPH in individuals with T2DM. This clinical beneﬁt is
achieved with a modest increase in pharmacy expenditures for
treating diabetes.
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OBJECTIVES: Despite extensive use of basal-bolus and pre-
mixed analog insulin therapy, real-world comparative effective-
ness of the regimens has not been determined. METHODS:
Patients with Type 2 diabetes at two US endocrinology practice
centers were randomized to insulin glargine plus glulisine
(GLAR/GLU, n = 106) or analog premix (n = 91). Subsequent to
randomization, patients continued treatment following center’s
usual practice with no additional therapeutic protocols. Data
collected at 0, 3, 6 and 9 months included A1C, hypoglycemia,
insulin dose, concomitant medications, and therapy change.
Medication costs were estimated using published average whole-
sale price. RESULTS: Treatment groups were comparable at
baseline with mean age 56 years, 46% male, 59% Caucasian,
and 38% African-American, duration of diabetes 13 years,
HbA1C 9.25%, and BMI 35.8 kg/m2. About 70% patients used
oral hypoglycemic agent(s) during 4 months before randomiza-
tion, 88% used insulin with mean daily dose of 71IU, and 29%
had chart records for hypoglycemia. Mean follow-up time was
183 days. 1 patient (1%) randomized to GLAR/GLU switched
to premix therapy relative to 9 (10%) randomized to premix
switched to GLAR/GLU. In ITT analysis, adjusted mean
follow-up HbA1C was 6.98% in GLAR/GLU vs. 7.57% in
premix (d = -0.59%, p = 0.009) and HbA1C reduction was
2.27% (95% CI: 1.63–2.91) vs. 1.68% (1.20–2.16). Mean
number of concomitant oral anti-diabetic agents were 0.94 vs.
1.22 (d = -0.28, p = 0.041). Mean daily insulin dose was 74IU
vs. 85IU (d = -11, p = 0.267). Hypoglycemia was recorded in
charts for 36% vs. 43% (d = -7%, p = 0.374) patients in GLAR/
GLU vs. premix. Daily costs for all anti-diabetic medications
were $9.8 in GLAR/GLU vs. $11.9 in premix (d = -$2.1,
p = 0.036). Treatment costs per 1% HbA1C reduction during
follow-up period (183 days) were $790 for GLAR/GLU vs.
$1,296 for premix. CONCLUSION: In real world practices,
glargine plus glulisine, relative to analogue premix, produces
improved glycemic control with lower total diabetes medication
costs.
PDB17
MEDICAL COSTS AMONG INDIVIDUALS WITH DIABETES,
HYPERTENSION OR HYPERCHOLESTEROLEMIA
Lage MJ1, Boye KS2
1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 2Eli Lilly
and Company, Indianapolis, IN, USA
OBJECTIVES: Diabetes, hypertension and high cholesterol are
all prevalent in the United States. The purpose of this research is
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to compare medical costs in a managed care setting for individu-
als with the following diagnoses: diabetes mellitus (DM), hyper-
tension (HYP), and hypercholesterolemia (HC). In so doing,
this research will allow payers to understand the comparative
resource implications of these common conditions. METHODS:
Data from the i3 LabRx Database were used for this study. Adult
patients who were diagnosed with DM (N = 2,815), HYP
(N = 6,073), or HC (N = 11,442) were included in the study.
Differences among the three groups were examined using chi-
square statistics for categorical variables and t-statistics for con-
tinuous variables. Two-year cost comparisons among the cohorts
were conducted using a multivariate regression that controlled
for patient characteristics, general health status and comorbid
conditions. RESULTS: Compared to the DM cohort, the HYP
cohort was signiﬁcantly older and less likely to be male, while the
HC cohort was more likely to be male. Individuals diagnosed
with HYP or HC had signiﬁcantly lower total direct two-year
medical costs compared to those in the DM cohort (-$4,588,
p < 0.0001; and -$9,062, p < 0.0001 respectively) as well as
signiﬁcantly lower inpatient costs (-$3,640, p < 0.0001;
-$13,463, p < 0.0001), and outpatient prescription drug costs
(-$1,518, p < 0.0001; -$2,823, p < 0.0001). In addition,
patients in the HYP or HC cohorts were found to have signiﬁ-
cantly lower disease-speciﬁc total direct two-year medical costs
(-$1017, p < 0.0001; -$4941, p < 0.0001, respectively) com-
pared to individuals in the DM cohort. CONCLUSION: Results
from this study indicated signiﬁcant differences in demographic
characteristics and comorbidities among individuals diagnosed
with DM, HYP, or HC. These differences translated into signiﬁ-
cant cost differences, with patients diagnosed with DM experi-
encing both higher total medical costs and higher disease-speciﬁc
medical costs than individuals diagnosed with either HYP or HC.
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OBJECTIVES: Thiazolidinediones (TZDs) were ﬁrst introduced
in the late 1990s as adjunctive oral therapy for patients with type
2 diabetes mellitus (T2DM). The comparative economic values
of TZD therapeutic options currently available in the US mar-
ketplace are not well characterized. We estimated the cost-
effectiveness of pioglitazone compared with rosiglitazone in
treating T2DM consistent with AMCP cost-effectiveness guide-
lines. METHODS: Clinical efﬁcacy and baseline parameters were
taken from Goldberg RB et al, 2005, and entered into a previ-
ously validated, Markov-based economic model for T2DM. The
model was used to project long-term improvements in clinical
and economic outcomes comparing pioglitazone with rosiglita-
zone. A series of Markov constructs simulated the progression of
diabetes-related complications (cardiovascular, neuropathy, renal
and eye disease). Transition probabilities and HbA1c-dependent
adjustments were derived from published epidemiological
studies. Costs of T2DM complications were taken from pub-
lished sources. Drug acquisition costs for pioglitazone and
rosiglitazone were assumed to be $4.91/day and $4.18/day,
respectively (WAC prices, 2007), and remained constant. A time
horizon of 35 years was used, with costs and clinical outcomes
discounted at 3% per annum. Univariate sensitivity analyses
were conducted to test robustness of the base case cost-
effectiveness ratio scenarios. RESULTS: The incremental life-
years and quality-adjusted life years gained for pioglitazone
versus rosiglitazone were 0.180 and 0.129 years, respectively, at
an overall increased cost of $3241 per patient over the simulation
period. Therefore, the incremental cost-effectiveness ratios were
$17,981/LY and $25,219/QALY gained, respectively, in our base
case analysis. One-way sensitivity analyses demonstrated that
with variation in key input parameters (discount rates, HbA1c,
lipid effects, etc.); cost-effectiveness ﬁndings were most sensitive
to changes in HbA1c and high density lipoprotein (HDL) effects.
CONCLUSION: Our economic modeling analysis suggests that
pioglitazone delivers superior economic value when compared to
rosiglitazone due to improved clinical outcomes speciﬁcally
related to HDL effects.
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OBJECTIVES: Sitagliptin was the ﬁrst dipeptidyl peptidase 4
(DDP-IV) inhibitor to be approved by the FDA. The com-
parative economic value of thiazolidinediones (TZDs) and the
new (DPP-IV) class of oral diabetes medications has not been
studied. We estimated the cost-effectiveness of pioglitazone
compared with sitagliptin in treating T2DM over a lifetime
horizon in the US setting. METHODS: Clinical efﬁcacy param-
eters for pioglitazone were extracted from Goldberg RB et al,
2005. Sitagliptin parameters were extracted from Aschner P
et al, 2006 and assumed no lipid effects. Both were entered into
a validated economic model for T2DM. A series of Markov
constructs simulated the progression of diabetes-related compli-
cations (cardiovascular, neuropathic, renal, and ophthalmic).
Transition probabilities and HbA1c-dependent adjustments
were derived from published epidemiological studies. Mean
baseline HBA1c was comparable (7.6% for pioglitazone,
8.04% for sitagliptin). Costs of diabetes complications were
taken from published sources. Drug acquisition costs for piogli-
tazone and sitagliptin were assumed to be $4.91/day and $4.86/
day, respectively (WAC prices, 2007), and continued over the
duration of the simulation. The time horizon was 35 years and
costs were discounted at 3% per annum. Univariate sensitivity
analyses were conducted to test the robustness of the base case
cost-effectiveness ratios. RESULTS: The incremental life-years
(LY) and quality-adjusted life years (QALYs) gained for piogli-
tazone versus sitagliptin were 0.111 and 0.075 years, respec-
tively, at an overall increased total health care cost of $359
per patient over the speciﬁed time horizon. Therefore, the
incremental cost-effectiveness ratios (ICER) were $3236/LY
and $4804/QALY gained for pioglitazone versus sitagliptin.
Sensitivity analyses demonstrated that the base case cost-
effectiveness ratios were most sensitive to changes in HbA1c
and high density lipoprotein (HDL) values. CONCLUSION:
Our economic modeling analysis suggests that pioglitazone may
deliver superior economic value when compared to sitagliptin
due to improved HbA1c and cardiovascular outcomes at rea-
sonable incremental cost.
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